Amphotericin B colloidal dispersion

ABLC = Amphotericin B Lipid Complex ABCD = Amphotericin B Colloidal Dispersion L-AMB = Liposomal Amphotericin B... [Pg.147]

Lipid-associated formulations of amphotericin B, liposomal amphotericin B (AmBisome) and amphotericin B lipid complex (Abelcet) have been approved for use in proven cases of candidiasis however, patients with invasive candidiasis have also been treated successfully with amphotericin B colloid dispersion (Amphotec or Amphocil). The lipid-associated formulations are less toxic but as effective as amphotericin B deoxycholate. [Pg.435]

Candida albicans, C. tropicalis, C parapsilosis and resolution of signs and symptoms of infection Remove existing central venous catheters when feasible, plus Amphotericin B IV 0.6 mg/k day or Fluconazole IV/po 6 mg/kg/day or An echinocandin or Amphotericin B IV 0.7 mg/kg/day plus fluconazole IV/po 800 mg/day Patients intolerant or refractory to other therapf Amphotericin B lipid complex IV 5 m k day Liposomal amphotericin B IV 3-5 mg/kg/day Amphotericin B colloid dispersion IV 2-6 mg/k day (continued)... [Pg.436]

Having a broad-spectrum fungicidal activity, amphotericin remains the mainstay of treatment of most invasive fungal infections. Compared with conventional amphotericin B deoxycholate, other lipid formulations of amphotericin (amphotericin B colloidal dispersion, amphotericin B lipid complex, and liposomal amphotericin B) facilitate treatment in patients with suspected and proven invasive mycoses, who are intolerant of or refractory to conventional amphotericin. [Pg.192]

Amphotericin deoxycholate versus amphotericin B colloidal dispersion... [Pg.196]

Amphotericin B colloidal dispersion During ABCD therapy 8.5% of patients developed nephrotoxicity compared with 21 % in those given amphotericin deoxycholate (5). [Pg.202]

Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of can-didemia in immunocompromised patients. Clin Infect Dis 1998 26(2) 461-7. [Pg.206]

Anaissie EJ, Mattiuzzi GN, Miller CB, Noskin GA, Gurwith MJ, Mamelok RD, Pietrelli LA. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998 42(3) 606-11. [Pg.206]

Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 1999 45(Suppl l) 67-76. [Pg.207]

Noskin G, PietreUi L, Gurwith M, Bowden R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999 23(7) 697-703. [Pg.207]

Anaissie EJ, GraybiU JR, Noskin GA, Oppenheim BA, Andres E, PietreUi LA. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis... [Pg.207]

Bowden R, Chandrasekar P, White MH, Li X, Pietrehi L, Gurwith M, van Bnrik JA, Laverdiere M, Safrin S, Wingard JR. A donble-blind, randomized, controhed trial of amphotericin B colloidal dispersion versns amphotericin B for treatment of invasive aspergillosis in immnnocom-promised patients. Chn Infect Dis 2002 35(4) 359-66. [Pg.209]

Clemons KV, Stevens DA. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 1991 35 1829-33. [Pg.349]

Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992 36 2656-60. [Pg.349]

DoubekM, Mayer J, Lauschova I, et ai. Comparison of the effect of amphotericin Bdesoxycholate and amphotericin B colloidal dispersion on renal functions and renal morphology in rats. Nephrology (Carlton) 2005 10 57-62. [Pg.350]

Krejcirova L, Lauschova I, Horky D, et ai. Influence of amphotericin B deoxycholate or amphotericin B colloidal dispersion on renal tubule epithelium in rat. Biomed Pap Med Eac Univ Palacky Olomouc Czech Repub 2004 148 221-3. [Pg.350]

White MH, Bowden RA, Sandler ES, et ai. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998 27 296-302. [Pg.350]

Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000 22 242-6. [Pg.351]

Timmers GJ, Zweegman S, Simoons-Smit AM, et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000 25 879-84. [Pg.351]

ABCD amphotericin B colloidal dispersion ANCA anti-neutrophil cytoplasmic antibody... [Pg.945]

In patients intolerant to amphotericin B or fluconazole, one of the lipid formulations may he used. In a randomized trial, amphotericin B lipid complex (ABLC) was found to he equivalent to 0.6-1 mg/kg per day of amphotericin B, and open-lahel therapy with amphotericin B colloid dispersion (ABCD) has been successful. [Pg.2181]

The use of deoxycholate amphotericin B frequently is associated with the development of induced nephrotoxicity. In an attempt to decrease the incidence of nephrotoxicity, three lipid formulations of amphotericin B have been developed and approved for use in humans amphotericin B lipid complex (ABLC, Abelcet Enzon Pharmaceuticals), amphotericin B colloidal dispersion (ABCD, Amphotec Inter-mune Pharmaceuticals), and liposomal amphotericin B (AmBisome Gilead Pharmaceuticals). In these preparations, amphotericin B is incorporated into the phospholipid bilayer membrane rather than in the enclosed aqueous phase. [Pg.2185]

White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997 24 635-642. [Pg.2214]

Amphotericin B is complexed with deoxycholate (C-AMB) and marketed as a lyophilized powder (fungizone) containing 50 mg of amphotericin B that forms a colloid in water. Three lipid formulations of amphotericin B are marketed in the U.S. Amphotericin B colloidal dispersion (ABCD, AMPHOTEC, amphocil) contains equimolar amounts of amphotericin B and cholesteryl sulfate. AMBISOME is a small, unilamellar vesicle formulation that combines amphotericin B (50 mg) with 350 mg of lipid (phosphatidylcholine, cholesterol, and distearoylphosphatidylglycerol, in molar ratio of 10 5 4) in an -10% molar ratio. Amphotericin B lipid complex (ABLC, abelcet) contains dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol in a 7 3 mixture with -35 mol% of amphotericin B. [Pg.798]

Fungizone Amphotericin B colloidal dispersion 10-50 mg in an infusion bag/bottle 500 mL... [Pg.284]

Observational studies In clinical trials, in the absence of premedication, the rates of infusion-related reactions have been higher with amphotericin B colloidal dispersion (ABCD) than with other forms of amphotericin B, including amphotericin B deoxy-cholate [7 ]. Data on pre-medication practices and infusion-related reactions in 170 patients (median age 37 years 52% men) who received 1230 infusions of ABCD (mean dose 2.8 mg/kg/day) have been captured in a multicenter, worldwide, observational registry [8 ]. Treatment was according to the site s standard treatment practice. Common pre-medications included glucocorticoids, antihistamines, paracetamol (acetaminophen), and metamizole. The overall rate of infusion-related reactions... [Pg.542]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...